639 related articles for article (PubMed ID: 22249628)
1. The role of molecular markers and tumor histological type in central lymph node metastasis of papillary thyroid carcinoma.
Paulson L; Shindo M; Schuff K; Corless C
Arch Otolaryngol Head Neck Surg; 2012 Jan; 138(1):44-9. PubMed ID: 22249628
[TBL] [Abstract][Full Text] [Related]
2. Role of chronic lymphocytic thyroiditis in central node metastasis of papillary thyroid carcinoma.
Paulson LM; Shindo ML; Schuff KG
Otolaryngol Head Neck Surg; 2012 Sep; 147(3):444-9. PubMed ID: 22547555
[TBL] [Abstract][Full Text] [Related]
3. Prediction of occult central lymph node metastasis in papillary thyroid carcinoma by preoperative BRAF analysis using fine-needle aspiration biopsy: a prospective study.
Joo JY; Park JY; Yoon YH; Choi B; Kim JM; Jo YS; Shong M; Koo BS
J Clin Endocrinol Metab; 2012 Nov; 97(11):3996-4003. PubMed ID: 22930785
[TBL] [Abstract][Full Text] [Related]
4. The BRAF mutation is predictive of aggressive clinicopathological characteristics in papillary thyroid microcarcinoma.
Lin KL; Wang OC; Zhang XH; Dai XX; Hu XQ; Qu JM
Ann Surg Oncol; 2010 Dec; 17(12):3294-300. PubMed ID: 20953721
[TBL] [Abstract][Full Text] [Related]
5. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
[TBL] [Abstract][Full Text] [Related]
6. BRAF V600E mutation independently predicts central compartment lymph node metastasis in patients with papillary thyroid cancer.
Howell GM; Nikiforova MN; Carty SE; Armstrong MJ; Hodak SP; Stang MT; McCoy KL; Nikiforov YE; Yip L
Ann Surg Oncol; 2013 Jan; 20(1):47-52. PubMed ID: 22941165
[TBL] [Abstract][Full Text] [Related]
7. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.
Costa AM; Herrero A; Fresno MF; Heymann J; Alvarez JA; Cameselle-Teijeiro J; García-Rostán G
Clin Endocrinol (Oxf); 2008 Apr; 68(4):618-34. PubMed ID: 18070147
[TBL] [Abstract][Full Text] [Related]
8. Central nodal metastases in papillary thyroid carcinoma based on tumor histologic type and focality.
Salter KD; Andersen PE; Cohen JI; Schuff KG; Lester L; Shindo ML; Sauer D; Gross ND
Arch Otolaryngol Head Neck Surg; 2010 Jul; 136(7):692-6. PubMed ID: 20644065
[TBL] [Abstract][Full Text] [Related]
9. Lymph node management in clinically node-negative patients with papillary thyroid carcinoma.
Vergez S; Sarini J; Percodani J; Serrano E; Caron P
Eur J Surg Oncol; 2010 Aug; 36(8):777-82. PubMed ID: 20584589
[TBL] [Abstract][Full Text] [Related]
10. No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan.
Liu RT; Chen YJ; Chou FF; Li CL; Wu WL; Tsai PC; Huang CC; Cheng JT
Clin Endocrinol (Oxf); 2005 Oct; 63(4):461-6. PubMed ID: 16181240
[TBL] [Abstract][Full Text] [Related]
11. BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid Rodolico V; Cabibi D; Pizzolanti G; Richiusa P; Gebbia N; Martorana A; Russo A; Amato MC; Galluzzo A; Giordano C
Cancer; 2007 Sep; 110(6):1218-26. PubMed ID: 17685465
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for central neck lymph node metastasis of clinically noninvasive, node-negative papillary thyroid microcarcinoma.
Park JP; Roh JL; Lee JH; Baek JH; Gong G; Cho KJ; Choi SH; Nam SY; Kim SY
Am J Surg; 2014 Sep; 208(3):412-8. PubMed ID: 24602323
[TBL] [Abstract][Full Text] [Related]
13. [An investigation of BRAF mutation in papillary thyroid carcinoma and its clinical value].
Gong RX; Zhou Y; Luo SH; Zhang L; Zhou B
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2009 Jun; 26(3):310-3. PubMed ID: 19504446
[TBL] [Abstract][Full Text] [Related]
14. [BRAF(T1799A) mutation in the primary tumor as a marker of risk, recurrence, or persistence of papillary thyroid carcinoma].
Cañadas Garre M; López de la Torre Casares M; Becerra Massare P; López Nevot MÁ; Villar Del Moral J; Muñoz Pérez N; Vílchez Joya R; Montes Ramírez R; Llamas Elvira JM
Endocrinol Nutr; 2011 Apr; 58(4):175-84. PubMed ID: 21441079
[TBL] [Abstract][Full Text] [Related]
15. Does BRAF V600E mutation predict aggressive features in papillary thyroid cancer? Results from four endocrine surgery centers.
Li C; Aragon Han P; Lee KC; Lee LC; Fox AC; Beninato T; Thiess M; Dy BM; Sebo TJ; Thompson GB; Grant CS; Giordano TJ; Gauger PG; Doherty GM; Fahey TJ; Bishop J; Eshleman JR; Umbricht CB; Schneider EB; Zeiger MA
J Clin Endocrinol Metab; 2013 Sep; 98(9):3702-12. PubMed ID: 23969188
[TBL] [Abstract][Full Text] [Related]
16. Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)).
Carta C; Moretti S; Passeri L; Barbi F; Avenia N; Cavaliere A; Monacelli M; Macchiarulo A; Santeusanio F; Tartaglia M; Puxeddu E
Clin Endocrinol (Oxf); 2006 Jan; 64(1):105-9. PubMed ID: 16402937
[TBL] [Abstract][Full Text] [Related]
17. Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation.
Yip L; Nikiforova MN; Carty SE; Yim JH; Stang MT; Tublin MJ; Lebeau SO; Hodak SP; Ogilvie JB; Nikiforov YE
Surgery; 2009 Dec; 146(6):1215-23. PubMed ID: 19958951
[TBL] [Abstract][Full Text] [Related]
18. Predictive factors for ipsilateral or contralateral central lymph node metastasis in unilateral papillary thyroid carcinoma.
Koo BS; Choi EC; Yoon YH; Kim DH; Kim EH; Lim YC
Ann Surg; 2009 May; 249(5):840-4. PubMed ID: 19387316
[TBL] [Abstract][Full Text] [Related]
19. [Multifocal papillary thyroid carcinoma: clinical analysis of 168 cases].
Lin YK; Sheng JM; Zhao WH; Wang WB; Yu XF; Teng LS; Ma ZM
Zhonghua Wai Ke Za Zhi; 2009 Mar; 47(6):450-3. PubMed ID: 19595234
[TBL] [Abstract][Full Text] [Related]
20. Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature.
Fugazzola L; Puxeddu E; Avenia N; Romei C; Cirello V; Cavaliere A; Faviana P; Mannavola D; Moretti S; Rossi S; Sculli M; Bottici V; Beck-Peccoz P; Pacini F; Pinchera A; Santeusanio F; Elisei R
Endocr Relat Cancer; 2006 Jun; 13(2):455-64. PubMed ID: 16728573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
